Medtronic ( MDT 2.27%) and Johnson & Johnson ( JNJ 1.64%) are two very healthy, high-yielding dividend stocks. This makes ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

The massive robot-making, pacemaker-inventing medtech company Medtronic is facing a financial snag: the humble stapler.

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

Medtronic beat Wall Street estimates for third-quarter profit on Tuesday, partly helped by demand for its diabetes devices, ...

Shares of Medtronic PLC MDT rallied 2.27% to $89.94 Friday, on what proved to be an all-around poor trading session for the ...

The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...

Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of $93.00.